(Aug. 19, '26) Prestige BioLogics surpassed KRW 10 billion in quarterly revenue for the first time.According to Prestige BioLogics on the 19th, the Company recorded revenue of KRW 11.47 billion in Q4 of FY2026 (April–June 2026).This represents an increase of more than five-fold compared to the previous quarter's revenue of KRW 2.27 billion.Throughout FY2026, Prestige BioLogics continued to expand its order base, signing a total of six new CDMO (contract development and manufacturing) contracts with domestic and international clients, worth approximately KRW 41.2 billion.As these new contracts were sequentially converted into production and revenue, they had a positive impact on this quarter's results.Kim Jin-woo, CEO of Prestige BioLogics, said, "The widened loss despite revenue growth was mainly due to items such as inventory assets, convertible bonds (CBs), and impairment of certain production equipment, with limited impact on actual cash flow."He added, "Surpassing KRW 10 billion in Q4 revenue is a clear sign that the order base we've been building is now materializing into results."| Source: Asia Economy (아시아경제) | https://www.asiae.co.kr/article/2026081908554428168 This English version is a translation provided by the Company for reference purposes. The original article was written and published in Korean by Asia Economy.

(July 02, 2026) Prestige Biopharma Enters Strategic MOU with Charles River , a Global Contract Research Organization● Collaborating to Accelerate Development and Commercialization of Biosimilars and Novel Antibody Therapeutics● Integrating a Full-Coverage Value Chain: From Discovery, Preclinical, and Safety Testing to Process Development and GMP Manufacturing● Driving Global Business Expansion and CDMO Pipeline Growth through Strategic Networking and Joint MarketingSINGAPORE/SEOUL — June 22, 2026 — Prestige Biopharma Limited (KRX: 950210), a global biopharmaceutical company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Charles River Laboratories International, Inc. (NYSE: CRL), a premier global life sciences company headquartered in Massachusetts, U.S., to collaborate on the development, testing, analysis, and manufacturing of biopharmaceuticals.The collaboration leverages the unique strengths of both organizations: Charles River’s world-class expertise in preclinical and analytical services and Prestige Biopharma Group’s robust capabilities in antibody therapeutic development and Contract Development and Manufacturing Organization (CDMO) services. Together, the companies aim to streamline and accelerate the path to commercialization for biosimilars and novel biologics.The collaboration integrates specialized services across the entire drug development lifecycle, ranging from discovery and preclinical safety assessments to analytical testing, process development, and GMP manufacturing. Key areas of cooperation include:☉ Analytical method development and validation☉ Quality control (QC) and batch release testing☉ Biosafety, viral safety, and cell line characterization☉ GLP-compliant toxicology studies☉ Pharmacokinetic (PK) and pharmacodynamic (PD) researchCharles River, having supported the development of over 80% of all drugs approved by the U.S. Food and Drug Administration (FDA) over the past five years, brings unparalleled expertise to this collaboration. By utilizing Charles River’s comprehensive testing and analytical solutions with Prestige Biopharma Group’s antibody manufacturing expertise, the companies intend to offer enhanced support for clients seeking entry into major regulated markets, including the U.S. and Europe.The collaboration also initiates a joint business development strategy utilizing the companies' respective global networks. Charles River will refer clients requiring biopharmaceutical process development and GMP manufacturing to Prestige Biopharma Group, while Prestige Biopharma Group will connect clients in need of early-stage discovery, preclinical toxicology, and bioanalytical services to Charles River. With Charles River’s core focus on preclinical drug development and analytical testing services, this collaboration creates a highly synergistic model that optimizes both companies’ capabilities to expand their respective project pipelines and capitalize on new business opportunities.Furthermore, the companies plan to increase their global presence through joint marketing initiatives, including participation in major industry conferences, joint seminars, and the collaborative development of white papers and technical marketing materials detailing scientific breakthroughs."This collaboration with Charles River, a global leader in preclinical and testing services, marks a pivotal milestone in directly connecting our antibody development and manufacturing expertise with a broader global client network," said a spokesperson for Prestige Biopharma. "By combining our specialized skill sets, we will significantly enhance the efficiency of biopharmaceutical development while aggressively expanding our global CDMO order pipeline and long-term business development opportunities."Prestige Biopharma Group continues to solidify its global footprint by focusing on its core businesses: biosimilars, novel drug development, and CDMO services. Building on recent successful collaborations with global pharmaceutical leaders, the group remains committed to strengthening its foundation for sustained growth in the biopharmaceutical development and manufacturing sector.

(June 10, 2026) Cumulative order backlog surpasses KRW 65 billion as of March 2026; pursuing commercial manufacturing partnerships through its “Scale-Bridge CDMO” strategyPrestige Biologics is accelerating the expansion of its CDMO (Contract Development and Manufacturing Organization) business by securing an additional contract to manufacture biosimilar clinical trial materials for a domestic biopharmaceutical company with experience in commercializing biosimilars in global markets.The company announced on June 10 that it had been awarded a contract by a Korean biotechnology company to manufacture biosimilar clinical trial materials required for pre-commercialization activities. The contract will remain in effect through the end of March 2027. The identity of the client and the product involved were not disclosed due to confidentiality obligations.The new agreement follows a recently signed CDMO contract with a major pharmaceutical company in Asia and is regarded as part of the company’s broader strategy to expand its order pipeline. As of the end of March 2026, Prestige Biologics had secured a cumulative order backlog of approximately KRW 65 billion and has now entered a phase in which these contracts are being translated into actual production activities and revenue generation.The product covered under the agreement is reported to be a biosimilar of a global blockbuster biologic. Given that the project is approaching the commercialization stage, the company expects the possibility of securing future commercial manufacturing contracts. Prestige Biologics plans to further strengthen its relationship with the client through this clinical trial material production project and pursue additional manufacturing opportunities.The company stated that it has established strong quality competitiveness through its experience in obtaining Good Manufacturing Practice (GMP) certifications from both the Korean Ministry of Food and Drug Safety (MFDS) and the European Medicines Agency (EMA), as well as through its successful preparation for inspections by global regulatory authorities. Based on these capabilities, Prestige Biologics has developed a manufacturing and quality management system that meets global standards.The company has also been strengthening its “Scale-Bridge CDMO” strategy, which is designed to ensure continuity from clinical development through commercial manufacturing. The strategy focuses on leveraging manufacturing experience gained during early-stage development to support subsequent clinical and commercial production, thereby reducing technology transfer burdens and manufacturing risks for customers.In parallel, Prestige Biologics continues to focus on improving profitability. The company has enhanced cost management efficiency by addressing a previous accounting structure under which raw material costs were recognized before corresponding revenue. As a result, management expects improvements in operating profit. The company intends to pursue both top-line growth and profitability through repeat orders and increasingly sophisticated cost management systems.A company representative commented:“This follow-on contract demonstrates that a customer with proven experience in commercializing biosimilars globally has once again selected Prestige Biologics based on our validated CDMO capabilities.”The representative added:“We intend to leverage our experience in producing pre-commercialization clinical trial materials to secure future commercial manufacturing opportunities. Through repeat business and strengthened cost management capabilities, we will continue to enhance both the growth potential and profitability of our CDMO business.”

 Prestige Biologics at Bioplus Interphex Korea 2025 📍 Location: COEX, Seoul📅 Dates: October 15 – 17, 2025 Prestige Biologics will be participating in Bioplus Interphex Korea 2025 — a comprehensive bio-pharmaceutical exhibition featuring keynote sessions, over 30 conferences, partnering, open innovation and networking opportunities to build global business connections.  We look forward to welcoming you at our booth, engaging in partnering discussions, and sharing our vision and goals for the future. #BioplusInterphexKorea #PrestigeBiologics #Biopharma #Innovation #Partneringhttps://www.bioplusinterphex.co.kr/ko-kr/program/partnering.html 

Interphex Japan 2025 Tokyo ShowEvent Dates : July 9-11, 2025City/Country : Tokyo, JapanWebsite : www.interphex.jp/tokyo/en-gb.htmlRESERVEThank you for your interest in exploring potential opportunities with us.Please let us know your preferred date and time for an in-person meeting, along with the topic you would like to discuss.Once we receive your request, we will reach out to you to confirm the suitable timeslot and the company delegate who will be attending.INQUIRE

KASBP 2025Event Dates : June 13-14, 2025City/Country : Rockville, USAWebsite : www.kasbp.orgRESERVEThank you for your interest in exploring potential opportunities with us.Please let us know your preferred date and time for an in-person meeting, along with the topic you would like to discuss.Once we receive your request, we will reach out to you to confirm the suitable timeslot and the company delegate who will be attending.INQUIRE

(Aug. 19, '26) Prestige BioLogics surpassed KRW 10 billion in quarterly revenue for the first time.According to Prestige BioLogics on the 19th, the Company recorded revenue of KRW 11.47 billion in Q4 of FY2026 (April–June 2026).This represents an increase of more than five-fold compared to the previous quarter's revenue of KRW 2.27 billion.Throughout FY2026, Prestige BioLogics continued to expand its order base, signing a total of six new CDMO (contract development and manufacturing) contracts with domestic and international clients, worth approximately KRW 41.2 billion.As these new contracts were sequentially converted into production and revenue, they had a positive impact on this quarter's results.Kim Jin-woo, CEO of Prestige BioLogics, said, "The widened loss despite revenue growth was mainly due to items such as inventory assets, convertible bonds (CBs), and impairment of certain production equipment, with limited impact on actual cash flow."He added, "Surpassing KRW 10 billion in Q4 revenue is a clear sign that the order base we've been building is now materializing into results."| Source: Asia Economy (아시아경제) | https://www.asiae.co.kr/article/2026081908554428168 This English version is a translation provided by the Company for reference purposes. The original article was written and published in Korean by Asia Economy.

(July 02, 2026) Prestige Biopharma Enters Strategic MOU with Charles River , a Global Contract Research Organization● Collaborating to Accelerate Development and Commercialization of Biosimilars and Novel Antibody Therapeutics● Integrating a Full-Coverage Value Chain: From Discovery, Preclinical, and Safety Testing to Process Development and GMP Manufacturing● Driving Global Business Expansion and CDMO Pipeline Growth through Strategic Networking and Joint MarketingSINGAPORE/SEOUL — June 22, 2026 — Prestige Biopharma Limited (KRX: 950210), a global biopharmaceutical company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Charles River Laboratories International, Inc. (NYSE: CRL), a premier global life sciences company headquartered in Massachusetts, U.S., to collaborate on the development, testing, analysis, and manufacturing of biopharmaceuticals.The collaboration leverages the unique strengths of both organizations: Charles River’s world-class expertise in preclinical and analytical services and Prestige Biopharma Group’s robust capabilities in antibody therapeutic development and Contract Development and Manufacturing Organization (CDMO) services. Together, the companies aim to streamline and accelerate the path to commercialization for biosimilars and novel biologics.The collaboration integrates specialized services across the entire drug development lifecycle, ranging from discovery and preclinical safety assessments to analytical testing, process development, and GMP manufacturing. Key areas of cooperation include:☉ Analytical method development and validation☉ Quality control (QC) and batch release testing☉ Biosafety, viral safety, and cell line characterization☉ GLP-compliant toxicology studies☉ Pharmacokinetic (PK) and pharmacodynamic (PD) researchCharles River, having supported the development of over 80% of all drugs approved by the U.S. Food and Drug Administration (FDA) over the past five years, brings unparalleled expertise to this collaboration. By utilizing Charles River’s comprehensive testing and analytical solutions with Prestige Biopharma Group’s antibody manufacturing expertise, the companies intend to offer enhanced support for clients seeking entry into major regulated markets, including the U.S. and Europe.The collaboration also initiates a joint business development strategy utilizing the companies' respective global networks. Charles River will refer clients requiring biopharmaceutical process development and GMP manufacturing to Prestige Biopharma Group, while Prestige Biopharma Group will connect clients in need of early-stage discovery, preclinical toxicology, and bioanalytical services to Charles River. With Charles River’s core focus on preclinical drug development and analytical testing services, this collaboration creates a highly synergistic model that optimizes both companies’ capabilities to expand their respective project pipelines and capitalize on new business opportunities.Furthermore, the companies plan to increase their global presence through joint marketing initiatives, including participation in major industry conferences, joint seminars, and the collaborative development of white papers and technical marketing materials detailing scientific breakthroughs."This collaboration with Charles River, a global leader in preclinical and testing services, marks a pivotal milestone in directly connecting our antibody development and manufacturing expertise with a broader global client network," said a spokesperson for Prestige Biopharma. "By combining our specialized skill sets, we will significantly enhance the efficiency of biopharmaceutical development while aggressively expanding our global CDMO order pipeline and long-term business development opportunities."Prestige Biopharma Group continues to solidify its global footprint by focusing on its core businesses: biosimilars, novel drug development, and CDMO services. Building on recent successful collaborations with global pharmaceutical leaders, the group remains committed to strengthening its foundation for sustained growth in the biopharmaceutical development and manufacturing sector.

 Prestige Biologics at Bioplus Interphex Korea 2025 📍 Location: COEX, Seoul📅 Dates: October 15 – 17, 2025 Prestige Biologics will be participating in Bioplus Interphex Korea 2025 — a comprehensive bio-pharmaceutical exhibition featuring keynote sessions, over 30 conferences, partnering, open innovation and networking opportunities to build global business connections.  We look forward to welcoming you at our booth, engaging in partnering discussions, and sharing our vision and goals for the future. #BioplusInterphexKorea #PrestigeBiologics #Biopharma #Innovation #Partneringhttps://www.bioplusinterphex.co.kr/ko-kr/program/partnering.html 

Interphex Japan 2025 Tokyo ShowEvent Dates : July 9-11, 2025City/Country : Tokyo, JapanWebsite : www.interphex.jp/tokyo/en-gb.htmlRESERVEThank you for your interest in exploring potential opportunities with us.Please let us know your preferred date and time for an in-person meeting, along with the topic you would like to discuss.Once we receive your request, we will reach out to you to confirm the suitable timeslot and the company delegate who will be attending.INQUIRE